Enfuvirtide-asetaat (T-20)
Alias:Fuzeon
Volgorde:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas No. : 159519-65-0
Molekulêre Formule : C204H301N51O64
Molekulêre gewig : 4492
Reinheid (HPLC) : 98.0%min.
Voorkoms : White to off-white amorphous solid
Enkele Onreinheid (HPLC) : 0.5%maks
Aminosuur samestelling : ±10% van teoreties
Peptied inhoud (N%) : ≥80,0%
Waterinhoud (Karl Fischer) : ≤8.0%
Trifluoracetaat inhoud(HPIC) : ≤12.0%
MS (ESI) : Konsekwent
Massabalans : 95.0~105,0%
Graad : Farmaseutiese Graad
Berging: Gesluit, hieronder 2 ~ 8℃ preservation
Gebruik : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
